February 2020, Volume 6, Issue 3

February 2020

Volume 6, Issue 3

This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.

Table of Contents

February 2020 Issue

Editor’s Corner: Don’t Forget to KISS Your Audience!

Saturday, February 1st, 2020
For hematologists around the world, a definite highlight of each year is the December American Society of Hematology (ASH) annual meeting, which now draws...
You Make the Call

Reader Responses: Does this patient with diabetes and thrombocytosis need a bone marrow biopsy?

Saturday, February 1st, 2020
Here’s how readers responded to a You Make the Call question about treatment of thrombocytosis in a patient with diabetes and ischemic cardiomyopathy. Disclaimer: ASH...

Expanding Your Lanes

Saturday, February 1st, 2020
In our December 2019 issue, outgoing Editor-in-Chief Mikkael Sekeres, MD, MS, penned his final Editor’s Corner, “My Patients, My Lanes,” in which he defined...

After the Trial Ends…

Saturday, February 1st, 2020
Our December 2019 issue featured a look at the unforeseen costs for patients who participate in clinical trials, including eventually paying for post-trial access...

February 2020 Issue

Are CAR T-Cell Therapies Worth the Costs?

Saturday, February 1st, 2020
Since the first chimeric antigen receptor (CAR) T-cell therapies gained FDA approval in 2017, the one-time treatments have led to unprecedented response rates in...

The High Price of Hemophilia

Saturday, February 1st, 2020
An estimated 20,000 people in the U.S. are living with the inherited bleeding disorder hemophilia, and more than 60% of them have moderate or...

Pulling Back the Curtain: Jean-Luc Harousseau, MD

Saturday, February 1st, 2020
In this edition, Jean-Luc Harousseau, MD, tells us about his double life as an international myeloma specialist and regional politician in France. When did you...

February 2020 Issue

You Make the Call

You Make the Call: Does this patient with diabetes and thrombocytosis need a bone...

Saturday, February 1st, 2020
This month, Mrinal S. Patnaik, MBBS, discusses treatment of thrombocytosis in a patient with diabetes and ischemic cardiomyopathy. And don't forget to check out next...

February 2020 Issue

Asciminib Shows Durable Clinical Activity in Heavily Pretreated CML

Saturday, February 1st, 2020
In a phase I, dose-escalation study, treatment with asciminib was active and associated with durable responses in more than half of patients with chronic...
WIB_icon

Can a CAR T-Cell “Cocktail” Overcome Antigen Escape?

Saturday, February 1st, 2020
A sequential infusion of 2 third-generation chimeric antigen receptor (CAR) T cells targeting CD19 and CD22, respectively, was associated with a high response rate...

Treatment for Lymphoplasmacytic Lymphoma Receives Orphan Designation

Saturday, February 1st, 2020
The FDA granted orphan drug designation to CLR 131, a phospholipid-drug conjugate that selectively delivers the radioisotope iodine-131 to tumor cells. CLR 131 is being...

FDA Places Partial Hold on Clinical Trials of Lacutamab for Advanced T-Cell Lymphomas

Saturday, February 1st, 2020
The FDA has placed a partial clinical hold on the phase II TELLOMAK trial, which is evaluating the safety and efficacy of lacutamab in...
WIB_icon

Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome

Saturday, February 1st, 2020
In a small study of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...

Defining the Goals of Venetoclax Treatment in Relapsed/Refractory CLL

Saturday, February 1st, 2020
Achieving undetectable measurable residual disease (MRD) predicts a better clinical outcome in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax,...
The Society Pages

Moffitt Officials Resign, HHS Awards $319 Million to National Health Service Corps, and more

Saturday, February 1st, 2020
Edward P. Evans Foundation Awards $10 Million in Funding for MDS Research Washington University School of Medicine in St. Louis and Dana-Farber Cancer Institute in...
ASH Directions

ASH Announces 2020 Scholar Awards and New ASH Clinical Practice Guidelines on ITP

Saturday, February 1st, 2020
Hats Off to the Recipients of the 2020 ASH Scholar Awards! The American Society of Hematology (ASH) has announced the 39 recipients of its 2020...

Drug Prices Increase by an Average of 5.8% for 2020

Saturday, February 1st, 2020
On January 1, 2020, more than 60 pharmaceutical companies raised list prices on hundreds of medications by an average of 5.8%. Nearly all price...

Study Finds Hospital Mergers Failed to Improve Quality of Care

Saturday, February 1st, 2020
Research published in the New England Journal of Medicine found that the recent wave of health care mergers and acquisitions had no substantial impact...

ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma

Saturday, February 1st, 2020
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP)...

February 2020 Issue

Can Biomarkers Predict Myeloma Patients’ Response to Venetoclax?

Saturday, February 1st, 2020
In an analysis of the phase III BELLINI trial, researchers identified 2 biomarkers that predict response to venetoclax in patients with relapsed/refractory multiple myeloma...

Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia

Saturday, February 1st, 2020
Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...

ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With...

Saturday, February 1st, 2020
Watch our interview with Megan C. Brown, MD. Researchers at Children’s Healthcare of Atlanta (CHOA) have developed an emergency department (ED)–based protocol that helps standardize...

Decitabine Maintenance May Improve Survival in Older Patients With AML

Saturday, February 1st, 2020
One year of maintenance therapy with brief monthly courses of intravenous decitabine was associated with improved overall survival (OS) among older patients with acute...